Editorial Perspectives On Patient Recruitment

  1. Hybrid Trials Are Impacting Clinical Research, But Do Patients Want Them? 11/11/2021

    Clinical trials continue to evolve and have become increasingly complex. Studies now have more procedures, visits, and time spent at clinics during those visits. The Center for Information and Study on Clinical Research Participation (CISCRP) is celebrating its eighth year of focusing on the patient experience in clinical trials via its Perceptions and Insights study.

  2. 4 Factors Preventing Diversity In Trials – And How To Overcome Them 11/9/2021

    A study conducted by advocacy group For The Breast of Us along with Sommer Consulting sought to determine the factors keeping women of color from participating in breast cancer clinical trials. Founded in 2019, For The Breast of Us is the first online community dedicated to women of color affected by breast cancer.

  3. Decentralized Trials Can Overcome The Challenges Of Rare Disease Patients 10/5/2021

    There are 400 million people worldwide who are impacted by more than 7,000 identifiable rare diseases. While individual rare diseases are uncommon, approximately 5% of the world’s population suffers from one. A new report from technology provider THREAD details how many of the clinical challenges posed by rare disease trials can be alleviated by decentralized trials.

  4. Seagen Leverages Partnerships to Understand Patient Perspectives 9/30/2021

    Patient recruitment, retention, and diversity in clinical trials has been an ongoing challenge. While there is an industry-wide effort underway to try and address these issues, they will not be truly impacted until researchers are able to create a better patient experience, do a better job of reaching patients from diverse communities, building true relationships, and working to co-create solutions as equal partners.

  5. Liver Disease Requires A Patient-Centric Approach To Trials 9/1/2021

    89bio is focused on two large markets which CEO Rohan Palekar believes are underserved. The first is fatty liver disease, which in its late stages is called non-alcoholic steatohepatitis (NASH). The second is severe hypertriglyceridemia, or high levels of fat in the blood. Creating trials for these diseases required a patient-centric approach.

  6. How An External Control Arm Changed Phase 3 Trials For Brain Cancer 8/19/2021

    Glioblastoma multiforme (GBM) is an aggressive and fatal form of brain cancer that can form in the brain or spinal cord. Unfortunately, drug development for patients with the disease has not seen much progress in decades. Dr. Fahar Merchant, president and CEO of Medicenna Therapeutics, a clinical stage immunotherapy company, is hoping to change that.

  7. The Four Essential Pillars of Successful Patient Centric Trials 8/12/2021

    Praxis Precision Medicines is a drug development company using genetic insights to focus on treatments for patients with CNS disorders. Praxis has patient centricity infused throughout the organization and believes taking care of patients and producing successful trials comes down to four essential factors: staff, sites, CROs, and patient insights.

  8. How One Biotech Is Taking An Innovative Approach To Alzheimer's Disease 7/15/2021

    Drug development in the Alzheimer’s space is difficult and has been plagued by successive failures over the last 18 years. One company working in that space felt it was time to take a new and innovative approach to find a treatment for patients.

  9. Merck's Efforts To Increase Patient Diversity 7/12/2021

    The barriers to minority participation in clinical research are well-known. Despite our knowledge of these barriers, the issues continue to exist. “It’s clear we need to do more of our research in the sites and communities that have access to the patients we are hoping to recruit,” says Luther Clark, deputy chief patient officer for Merck. “I believe one of the reasons pharma efforts to recruit a more diverse patient population have failed is because of our approach."

  10. 3 Steps To Address Diversity In Clinical Trials 6/23/2021

    The COVID pandemic in 2020 brought to light the significant disparities that exist in healthcare. But those same disparities also exist in the way clinical trials are structured and conducted. The Harvard Business Review recently published an article that outlines three recommendations for creating representative patient data.